Direct Acting Antiviral-Post Authorization Safety Study

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

March 9, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Hepatitis CHepatocellular Carcinoma
Trial Locations (62)

10016

New York University Langone Health, New York

10021

Weill Cornell Medical College, New York

10032

Columbia University Medical Center, New York

11030

Northwell Health - Center for Liver Disease, Manhasset

17033

Penn State Hershey Medical Center, Hershey

19104

University of Pennsylvania, Philadelphia

20007

Georgetown University, Washington D.C.

21202

Mercy Medical Center, Baltimore

22908

University of Virginia Transplant Center, Charlottesville

23226

Bon Secours Liver Institute of Virginia, Richmond

23298

Virginia Commonwealth University, Richmond

28204

Carolinas HealthCare System Center for Liver Disease, Charlotte

29403

Medical University of South Carolina, Charleston

30309

Piedmont Atlanta Hospital, Atlanta

30322

Emory University Hospital, Atlanta

32207

University of Florida - Health Gastroenerology, Jacksonville

32610

University of Florida Hepatology Research at CTRB, Gainesville

33136

Schiff Center for Liver Diseases, Miami

33606

Tampa General Medical Group, Tampa

33762

Gastro Florida, Clearwater

37212

Vanderbilt University Medical Center - GI Research Office, Nashville

39216

Southern Therapy and Advanced Research LLC, Jackson

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

55905

Mayo Clinic, Rochester

60611

Northwestern University Division of Gastroenterology and Hepatology, Chicago

60612

Rush University Medical Center, Chicago

63110

Saint Louis University, St Louis

70112

Tulane University School of Medicine, New Orleans

72205

University of Arkansas for Medical Sciences, Little Rock

75203

Clinical Research Institute@ Methodist Dallas Medical Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

76104

Baylor Scott & White All Saints, Fort Worth

77030

Research Specialists of Texas, Houston

77033

Research Specialists of Texas, Houston

85006

Banner University Medical Center, Phoenix

90033

Norris Comprehensive Cancer Center, Los Angeles

91105

California Liver Research Institute, Pasadena

94158

University of California - San Francisco, San Francisco

94304

Stanford University, Palo Alto

95817

University of California - Davis Clinical Trials, Sacramento

97213

Providence Health & Services Cancer Clinical Trials, Portland

98104

Harborview Medical Center, Seattle

98801

Wenatchee Valley Hospital & Clinics, Wenatchee

02215

Beth Israel Deaconess Medical Center, Boston

08901

Rutgers-Robert Wood Johnson Medical School, New Brunswick

Unknown

CHU de Nice - Hôpital L'Archet 2, Nice

Hôpitaux Universitaires Paris Centre, Paris

Charité - Universitätsmedizin Berlin, Berlin

Universitätsklinikum Frankfurt, Frankfurt

Universitätsklinikum Leipzig, Leipzig

Universitätsklinikum Magdeburg, Magdeburg

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

A.O.U.P. di Palermo, Palermo

Humanitas Mirasole IRCCS, Rozzano

"IRCCS Casa Sollievo della Sofferenza", San Giovanni Rotondo

Hospital Puerta de Hierro Majadahonda, Madrid

Clínica Universidad de Navarra, Pamplona

Hospital Universitario Marques de Valdecilla, Santander

Hospital Universitario Virgen del Rocío, Seville

Hospital Universitario Politècnic La Fe, Valencia

All Listed Sponsors
lead

Target PharmaSolutions, Inc.

INDUSTRY

NCT03707080 - Direct Acting Antiviral-Post Authorization Safety Study | Biotech Hunter | Biotech Hunter